Cargando…

Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus

INTRODUCTION: With the availability of an increasing number of therapeutic options for advanced prostate cancer (APC), optimal sequencing and combination of therapies have emerged to be the areas of challenges. In the Indian context, there is a dearth of consensus recommendations to guide clinicians...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Chirag, Vaid, Ashok K., Biswas, Ghanashyam, Batra, Sandeep, Dattatreya, Palanki S., Mohapatra, Prabrajya Narayan, Dabkara, Deepak, Gore, Adwaita, Bhagat, Sagar B., Patil, Saiprasad, Barkate, Hanmant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757405/
https://www.ncbi.nlm.nih.gov/pubmed/35025089
http://dx.doi.org/10.1007/s40487-021-00181-1
_version_ 1784632673588740096
author Desai, Chirag
Vaid, Ashok K.
Biswas, Ghanashyam
Batra, Sandeep
Dattatreya, Palanki S.
Mohapatra, Prabrajya Narayan
Dabkara, Deepak
Gore, Adwaita
Bhagat, Sagar B.
Patil, Saiprasad
Barkate, Hanmant
author_facet Desai, Chirag
Vaid, Ashok K.
Biswas, Ghanashyam
Batra, Sandeep
Dattatreya, Palanki S.
Mohapatra, Prabrajya Narayan
Dabkara, Deepak
Gore, Adwaita
Bhagat, Sagar B.
Patil, Saiprasad
Barkate, Hanmant
author_sort Desai, Chirag
collection PubMed
description INTRODUCTION: With the availability of an increasing number of therapeutic options for advanced prostate cancer (APC), optimal sequencing and combination of therapies have emerged to be the areas of challenges. In the Indian context, there is a dearth of consensus recommendations to guide clinicians regarding optimal sequencing of therapy in APC management. A Delphi-based consensus regarding optimal therapy sequencing in APC management was developed by an expert panel of medical oncologists from across India. METHODS: An expert scientific committee of 11 medical oncologists and an expert panel of 53 medical oncologists from India constituted the panel for the Delphi consensus. In the first phase, a questionnaire with 41 clinical statements was developed in several critical controversial areas in APC treatment. In the second phase, 29 clinical statements were reworked and sent to eight experts to obtain their opinions on best practices. The consensus ratings were based on a 9-point Likert scale. Based on the overall response, statements with a mean score of ≥ 7 with 1 outlier were considered as “consensus.” RESULTS: Degarelix was the preferred androgen deprivation therapy (ADT). While ADT plus docetaxel was the preferred option for metastatic castrate-sensitive/naïve prostate cancer patients with high-volume disease, ADT with abiraterone was the preferred choice for low-volume disease. Docetaxel was the preferred first-line treatment option in men who received ADT alone in the castrate-sensitive/naïve setting. For patients progressing on or after docetaxel for metastatic castrate-resistant prostate cancer (without prior abiraterone or enzalutamide), the experts reached a consensus on the use of enzalutamide as the preferred second-line treatment option. No consensus was reached for the third-line treatment options. CONCLUSION: This article is intended to serve as a guide to help clinicians discuss with their patients as part of the shared and multidisciplinary decision-making for improved APC management in India. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40487-021-00181-1.
format Online
Article
Text
id pubmed-8757405
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-87574052022-01-14 Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus Desai, Chirag Vaid, Ashok K. Biswas, Ghanashyam Batra, Sandeep Dattatreya, Palanki S. Mohapatra, Prabrajya Narayan Dabkara, Deepak Gore, Adwaita Bhagat, Sagar B. Patil, Saiprasad Barkate, Hanmant Oncol Ther Original Research INTRODUCTION: With the availability of an increasing number of therapeutic options for advanced prostate cancer (APC), optimal sequencing and combination of therapies have emerged to be the areas of challenges. In the Indian context, there is a dearth of consensus recommendations to guide clinicians regarding optimal sequencing of therapy in APC management. A Delphi-based consensus regarding optimal therapy sequencing in APC management was developed by an expert panel of medical oncologists from across India. METHODS: An expert scientific committee of 11 medical oncologists and an expert panel of 53 medical oncologists from India constituted the panel for the Delphi consensus. In the first phase, a questionnaire with 41 clinical statements was developed in several critical controversial areas in APC treatment. In the second phase, 29 clinical statements were reworked and sent to eight experts to obtain their opinions on best practices. The consensus ratings were based on a 9-point Likert scale. Based on the overall response, statements with a mean score of ≥ 7 with 1 outlier were considered as “consensus.” RESULTS: Degarelix was the preferred androgen deprivation therapy (ADT). While ADT plus docetaxel was the preferred option for metastatic castrate-sensitive/naïve prostate cancer patients with high-volume disease, ADT with abiraterone was the preferred choice for low-volume disease. Docetaxel was the preferred first-line treatment option in men who received ADT alone in the castrate-sensitive/naïve setting. For patients progressing on or after docetaxel for metastatic castrate-resistant prostate cancer (without prior abiraterone or enzalutamide), the experts reached a consensus on the use of enzalutamide as the preferred second-line treatment option. No consensus was reached for the third-line treatment options. CONCLUSION: This article is intended to serve as a guide to help clinicians discuss with their patients as part of the shared and multidisciplinary decision-making for improved APC management in India. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40487-021-00181-1. Springer Healthcare 2022-01-13 /pmc/articles/PMC8757405/ /pubmed/35025089 http://dx.doi.org/10.1007/s40487-021-00181-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Desai, Chirag
Vaid, Ashok K.
Biswas, Ghanashyam
Batra, Sandeep
Dattatreya, Palanki S.
Mohapatra, Prabrajya Narayan
Dabkara, Deepak
Gore, Adwaita
Bhagat, Sagar B.
Patil, Saiprasad
Barkate, Hanmant
Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus
title Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus
title_full Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus
title_fullStr Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus
title_full_unstemmed Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus
title_short Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus
title_sort sequencing of systemic therapies in the management of advanced prostate cancer in india: a delphi-based consensus
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757405/
https://www.ncbi.nlm.nih.gov/pubmed/35025089
http://dx.doi.org/10.1007/s40487-021-00181-1
work_keys_str_mv AT desaichirag sequencingofsystemictherapiesinthemanagementofadvancedprostatecancerinindiaadelphibasedconsensus
AT vaidashokk sequencingofsystemictherapiesinthemanagementofadvancedprostatecancerinindiaadelphibasedconsensus
AT biswasghanashyam sequencingofsystemictherapiesinthemanagementofadvancedprostatecancerinindiaadelphibasedconsensus
AT batrasandeep sequencingofsystemictherapiesinthemanagementofadvancedprostatecancerinindiaadelphibasedconsensus
AT dattatreyapalankis sequencingofsystemictherapiesinthemanagementofadvancedprostatecancerinindiaadelphibasedconsensus
AT mohapatraprabrajyanarayan sequencingofsystemictherapiesinthemanagementofadvancedprostatecancerinindiaadelphibasedconsensus
AT dabkaradeepak sequencingofsystemictherapiesinthemanagementofadvancedprostatecancerinindiaadelphibasedconsensus
AT goreadwaita sequencingofsystemictherapiesinthemanagementofadvancedprostatecancerinindiaadelphibasedconsensus
AT bhagatsagarb sequencingofsystemictherapiesinthemanagementofadvancedprostatecancerinindiaadelphibasedconsensus
AT patilsaiprasad sequencingofsystemictherapiesinthemanagementofadvancedprostatecancerinindiaadelphibasedconsensus
AT barkatehanmant sequencingofsystemictherapiesinthemanagementofadvancedprostatecancerinindiaadelphibasedconsensus